



Attorney Docket No.: 5253.200-US

PATENT

LY
10-9-98
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky et al.

Serial No.: 09/080,127

Group Art Unit: To Be Assigned

Filed: May 15, 1998

Examiner: To Be Assigned

For: Polypeptides Having Aminopeptidase Activity And Nucleic Acids Encoding Same

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. PTO-1449 Form
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on October 1, 1998.

Ann Quintero
(name of person mailing paper)

Ann Quintero
(signature of person mailing paper)


RECEIVED

OCT 07 1998

GROUP 1800

Attorney Docket No.: 5253.200-US

PATENT



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Blinkovsky et al.

Serial No.: 09/080,127

Group Art Unit: To Be Assigned

Filed: May 15, 1998

Examiner: To Be Assigned

For: Polypeptides Having Aminopeptidase Activity And Nucleic Acids Encoding Same

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED
OCT 07 1998
GROUP 1800

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. Abstract, File Medline, Stn. Medline Caesar Accession No. 1870 (XP-002077232), May 1977.
2. Abstract, File Medline, Stn Medline Caesar Accession No. 1872 (XP-002077233), October 1976.
3. Database WPI, Section Ch, Week 9130, (XP-002077234).
4. Database WPI, Section Ch, Week 9710, (XP-002076623).
5. WO 96/28542
6. DE 195 26 485 A1

7. EP 0 384 303
8. EP 0 480 104 A1
9. WO 97/43910

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: October 1, 1998



Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123